Can vilazodone (Viibryd) or Vraylar (cariprazine) cause false-positive results on drug screening?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Vilazodone or Vraylar Cause False-Positive Drug Screening?

Neither vilazodone (Viibryd) nor cariprazine (Vraylar) are expected to cause false-positive results on standard urine drug screening immunoassays based on available evidence.

Vilazodone (Viibryd)

Vilazodone does not cross-react with standard drug screening immunoassays. A controlled study specifically investigated this question by testing vilazodone and its major metabolite M17 at high concentrations (up to 100,000 ng/mL in urine and 2000 ng/mL in serum) against multiple immunoassay platforms 1. Despite initial computational predictions suggesting weak structural similarity to amphetamines and tricyclic antidepressants, actual laboratory testing demonstrated no cross-reactivity with:

  • Two different urine amphetamine immunoassays
  • Serum tricyclic antidepressant immunoassays

This study was prompted by two pediatric cases where vilazodone ingestion occurred alongside unexplained positive amphetamine screens, but the investigators concluded the positive results were coincidental rather than caused by vilazodone 1.

Clinical Context

The FDA label for vilazodone contains no warnings or precautions regarding false-positive drug screens 2. While vilazodone is mentioned in a 2023 pharmacovigilance review of psychiatric drugs causing false-positive amphetamine screens 3, the controlled experimental data from 2019 directly contradicts this concern 1.

Cariprazine (Vraylar)

Cariprazine has no documented association with false-positive drug screening results. The FDA label provides extensive pharmacokinetic data but makes no mention of drug screen interference 4. Key metabolic characteristics include:

  • Metabolized primarily via CYP3A4 and CYP2D6 to active metabolites (DCAR and DDCAR)
  • Only 1.2% excreted unchanged in urine
  • No structural similarity to commonly screened substances

Recent comprehensive safety analyses of cariprazine in clinical trials (involving over 1,500 patients) reported no issues with drug screening interference 5, 6. Additionally, a 2021 systematic review of false-positive drug tests with psychotropic medications did not identify cariprazine as a problematic agent 7.

Important Caveats

General Immunoassay Limitations

While these specific medications don't cause false positives, clinicians should understand that immunoassay-based drug screens are inherently susceptible to cross-reactivity 8, 9. When interpreting any drug screen:

  • Always obtain a complete medication list before interpreting results
  • Confirmatory testing with GC-MS or LC-MS/MS should be performed when results don't match clinical presentation
  • Other psychiatric medications (bupropion, trazodone, quetiapine, aripiprazole) have documented false-positive potential 7

When to Suspect a False Positive

If a patient taking vilazodone or cariprazine has a positive drug screen 8:

  1. The positive result is likely from actual substance use or another medication
  2. Review all medications, including over-the-counter drugs
  3. Consider timing of substance use relative to testing
  4. Order confirmatory testing if clinical suspicion is low
  5. Contact the testing laboratory for assistance with interpretation

Bottom line: You can confidently inform patients and employers that vilazodone and cariprazine do not interfere with standard drug screening tests.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.